Alzchem Group Ag · XETR:ACT
Alzchem — Q2 2026 Earnings Presentation
31 slides from Alzchem's earnings presentation, Jul 30, 2026
Slide 1: Agile Science Pure Results
AGILE SCIENCE PURE RESULTS
Slide 2: Q2 2026 Results Presentation
Q2 ANDREAS NIEDERMAIER, CEO ANDREAS LÖSLER, CFO 2026 July 30, 2026
Slide 3: Disclaimer
DISCLAIMER CAUTIONARY NOTE REGARDING FORWARD - LOOKING STATEMENTS This presentation contains forward - looking statements about the business, financial condition and earnings performance of the Alzchem Group. These statements are based on assumptions and projections resting upon currently available
Slide 4: Agenda – Analyst Presentation Q2 2026
AGENDA – ANALYST PRESENTATION Q2 2026 I. Executive Summary II. Business and financial details III. Back - Up
Slide 5: Highlights
HIGHLIGHTS Successful first half 2026 – all KPIs above prior year and on expected level Strong performance on group level : + 6% revenue growth Refurbishment of carbide furnace on finishing line + 14% EBITDA growth ✓ Volume and price growth in Specialty Chemicals Phased commissioning of new nitrogua
Slide 6: USA Expansion @ Bushy Park
USA EXPANSION @ BUSHY PARK Alzchem Establishes Nitroguanidine Production in the US Key highlights Two- pillar production Why Bushy Park? strategy • • Strategic site decision: Bushy Park Well established chemical park with existing (Berkeley County, South Carolina) modern infrastructure Production of
Slide 7: Agenda – Analyst Presentation Q2 2026
AGENDA – ANALYST PRESENTATION Q2 2026 I. Executive Summary II. Business and financial details III. Back - Up
Slide 8: Basics & Intermediates
BASICS & INTERMEDIATES The "Basics & Intermediates" segment comprises the production of basic and intermediate products that are marketed as independent products for example in agriculture, steel production and the automotive sector and as raw materials for the manufacture of specialty chemicals.
Slide 9: Basics & Intermediates Segment (in M€)
BASICS & INTERMEDIATES SEGMENT (in M€) Sales and EBITDA development on expected level with one - offs SALES +8.6% SALES EBITDA SALES ANALYSIS 41.8 40.9 41.9 42.6 43.3 38.7 DELTA DELTA 35.6 36.7 33.5 Q2 01 - 06 - 3.7% Volume + 11.5% - 2.2% 78.2 75.4 Price - 2.1% - 1.0% Currency - 0.8% - 0.4% Q2 Q3 Q4
Slide 10: Specialty Chemicals
SPECIALTY CHEMICALS The "Specialty Chemicals" segment produces and sells high - quality specialty chemical ingredients with strong growth perspectives.
Slide 11: Specialty Chemicals Segment (in M€)
SPECIALTY CHEMICALS SEGMENT (in M€) Ingredients for Specialty Applications push Sales and EBITDA SALES +8.8% SALES EBITDA SALES ANALYSIS 100.1 105.3 109.0 DELTA DELTA 94.5 97.2 85.8 89.0 87.0 +10.1% Q2 01 - 06 80.4 Volume + 2.8% + 4.6% 214.3 Price + 6.5% + 7.4% 194.6 Currency - 0.5% - 1.9% Q2 Q3 Q4
Slide 12: Other & Holding
OTHER & HOLDING The "Other & Holding" segment offers infrastructure and energy supply services at our locations for the chemicals segments and for external customers.
Slide 13: Other & Holding Segment (in M€)
OTHER & HOLDING SEGMENT (in M€) Regulated grid fees impact sales and result SALES SALES EBITDA COMMENTS +6.5% 8.5 7.7 8.1 7.6 • H1 revenue broadly stable year - on- year 7.5 7.1 7.0 6.6 6.7 with slight decline driven by lower - 2.6% electricity grid fee pass - throughs 14.7 14.3 • EBITDA effected by
Slide 14: Financial Overview
FINANCIAL OVERVIEW All KPI above prior year – net income follows EBITDA growth Q2 Q2 2025 2026 Alzchem Group qoq % yoy % 2025 2026 1-6 1-6 SALES (in M€) 142.9 155.2 +8.7% 287.6 303.9 +5.7% EBITDA (in M€) 29.1 32.2 +10.7% 56.5 64.5 +14.2% EBITDA margin (in %) 20.4% 20.7% +0.4 pp 19.6% 21.2% +1.6 pp E
Slide 15: Balance Sheet & Cashflow
BALANCE SHEET & CASHFLOW CAPEX and new financing structure with material impact on balance sheet COMMENTS Balance sheet KPIs (T€) 31.12.2025 30.06.2026 Deviation • Increase in balance sheet tota l resulting from increased CAPEX Balance sheet total 617,679 674,112 56,433 9.1% Inventories 116,004 110,
Slide 16: Outlook 2026
OUTLOOK 2026 (in M€) Ongoing growth in sales and EBITDA on expected level COMMENTS SALES EBITDA growth Outlook for 2026 confirmed to approx. 600 .0 M € Major assumptions are still valid growth • No significant impact of the Iran conflict; long - term disruption of +7% to approx. global supply chains
Slide 17: Financial Calendar
FINANCIAL CALENDAR Upcoming dates* JUL 30 2026 Half- year Financial Report 2026 COMMERZBANK and ODDO BHF Corporate SEP 1 2026 Conference, Frankfurt Berenberg Food Ingredients & Chemicals Conference, SEP 8 2026 London Berenberg and Goldman Sachs German Corporate SEP 23 2026 Conference, Munich SEP 24
Slide 18: Feedback
FEEDBACK We appreciate your feedback Were your expectations met? Are you missing any content? WE APPRECIATE YOUR FEEDBACK! Link QR - Code 18
Slide 19: Investor Relations
Investor Relations T +49 8621 86 - 2888 F +49 8621 86 - 502888 AGILE SCIENCE ir@alzchem.com PURE RESULTS www.alzchem.com
Slide 20: Agenda – Analyst Presentation Q2 2026
AGENDA – ANALYST PRESENTATION Q2 2026 I. Executive Summary II. Business and financial details III. Back - Up
Slide 21: Balance Sheet
BALANCE SHEET Alzchem Group ALZCHEM GROUP (IN T€) 31.12.2025 30.06.2026 Deviation ALZCHEM GROUP (IN T€) 31.12.2025 30.06.2026 Deviation Share capital 101,763 101,763 Intangible assets 3,530 3,784 255 7.2% RETAINED EARNINGS (+) / LOSS (-) 232,111 245,592 13,480 5.8% Tangible assets 276,980 328,868 51
Slide 22: Pension Accounting (IFRS)
PENSION ACCOUNTING (IFRS) Alzchem Group (M €) +0.5% 88.2 88.7 81.0 +0.1 +1.8 - 1.5 0.0 - 7.7 IN FINANCIAL PENSION SERVICE NET INTEREST PENSION PENSION PENSION DEFERRED PENSION STATEMENT PROVISION COSTS COSTS PAYMENTS REMEASURE - PROVISION TAX ASSETS LIABILITY 31.12.2025 EBITDA MENTS 30.06.2026 30.06
Slide 23: Income Statement
INCOME STATEMENT Alzchem Group Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 ALZCHEM GROUP (IN T€) Deviation (Q2) 2025 2025 2025 2025 2026 2026 2026 2026 Revenue 144,680 142,879 137,266 137,290 148,653 155,250 12,370 9% Increase (+) / Decrease (-) in inventories of finished goods and work in progress 11,436 3,433 624 545
Slide 24: Income Statement
INCOME STATEMENT Alzchem Group Q2 Q2 YTD YTD ALZCHEM GROUP (IN T€) Deviation (QoQ) Deviation (YoY) 2025 2026 Jun.2025 Jun.2026 Revenue 142,879 155,250 12,370 8.7% 287,559 303,902 16,343 5.7% Increase (+) / Decrease (-) in inventories of finished goods and work in progress 3,433 -11,145 -14,578 -424.
Slide 25: Cashflow Statement
CASHFLOW STATEMENT Alzchem Group Q2 Q2 1-6 1-6 CASHFLOW (IN M€) 2025 2026 2025 2026 Consolidated earnings before taxes 22,003 23,289 42,247 47,926 Depreciation on fixed and intangible assets 6,435 7,494 12,987 14,195 Decrease in pension provisions -606 -656 -1,374 -1,488 Loss (+) / Profit (-) from t
Slide 26: Segment Overview by Quarter
SEGMENT OVERVIEW BY QUARTER Alzchem Group SALES 2024 2025 2026 YTD Q2 2026 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Deviation PY (Q2) PY Actual Deviation PY (YOY) SALES T€ T€ T€ T€ T€ T€ T€ T€ T€ T€ T€ T€ T€ % T€ T€ T€ % Basics & Intermediates 49,299 41,848 40,927 41,929 42,638 35,605 43,309 33,539 36,66
Slide 27: Alzchem Group Locations
ALZCHEM GROUP LOCATIONS Production sites and sales companies BERLIN (GER) SUNDSVALL (SE) COVENTRY (UK) TROSTBERG (GER) SCHALCHEN (GER) HART a. d. ALZ (GER) WALDKRAIBURG (GER) © Alzchem Group AG / June 2026 SHANGHAI (CN) ATLANTA (USA) Production facilities in Germany (4) and Sweden (1) SALES COMPANY
Slide 28: “Verbund” – Fully Integrated Business Model
“VERBUND” – FULLY INTEGRATED BUSINESS MODEL Vertically integrated production of chemical products based on the NCN chain Segment Specialty Chemicals BENEFITS OF “VERBUND” Segment Basics & Inter - • Full control of product quality and specifications mediates • Lower costs • Higher financial predictab
Slide 29: Our Products and Markets
OUR PRODUCTS AND MARKETS Successful with proven and new products in various industries MAIN PRODUCTS DESCRIPTION END - MARKETS A nutritional additive for poultry and pigs Feed additive Creapure ® , premium brand for creatine monohydrate as ingredient in sports & health nutrition Food supplements Die
Slide 30: Our Products and Markets
OUR PRODUCTS AND MARKETS Successful with proven and new products in various industries MAIN PRODUCTS DESCRIPTION END - MARKETS Calcium carbide - based mixtures for hot metal desulphurization Steel industry Fuel for airbags. key production of the intermediate product Automotive INTERMEDIATES Pharmace
Slide 31: Key Share Data
KEY SHARE DATA Share details as of July 28, 2026 SHAREHOLDER SHARES OUTSTANDING 10,176,335 four two na GmbH STRUCTURE 10.14% LAST CLOSING PRICE EUR 173.30 Staluna Trade a. s. 9.90% MARKET CAPITALIZATION EUR 1,763.6 m TICKER ACT Löw SE 6.39% WKN A2YNT3 ISIN DE000A2YNT30 Frankfurt Stock Exchange – © A